AbbVie Inc. vs Bristol-Myers Squibb Company
In their latest fiscal years, AbbVie Inc. reported revenue of $61.16B and Bristol-Myers Squibb Company reported $48.19B — ABBV was 1.3× larger by revenue. Net income was $4.23B for ABBV and $7.05B for BMY.
| Latest fiscal year | ABBV · FY ended Dec 2025 | BMY · FY ended Dec 2025 |
|---|---|---|
| Revenue | $61.16B | $48.19B |
| Revenue growth | +8.6% | −0.2% |
| Operating income | $15.07B | — |
| Net income | $4.23B | $7.05B |
| Net margin | 6.9% | 14.6% |
| Diluted EPS | $2.36 | $3.46 |
| Operating cash flow | $19.03B | $14.16B |
| Total assets | $133.96B | $90.04B |
| Total liabilities | — | $71.53B |
| Shareholders' equity | −$3.27B | $18.47B |
| Cash & equivalents | $5.23B | $10.21B |
Revenue over time
Go deeper
Both columns use the same XBRL concepts where possible, but companies may define revenue and other line items differently. Banks, insurers and industrial companies are not directly comparable on margins. Source: SEC EDGAR XBRL company facts. Not investment advice.